- porno

Why VTI?

Validation Technologies, Inc. (VTI), an ISO 9001:2008 Certified Global Company, strives to maintain and inspire professional excellence by providing Validation, Commissioning, and Qualification (C&Q) Services to Pharmaceuticals, Biotechnology, Biologics, Medical Devices and FDA/Internationally regulated industries.  We have the experience, expertise, and commitment to provide the superior service required to meet all of your validation and compliance needs.

We offer a full spectrum of services such as computer validation, cleaning validation, process validation, clean room certification, temperature mapping, process equipment and facility qualification, and much more. Dedication to quality, personalized support and the success of your projects are the foundation of our company.

View all events ›

Upcoming Events

Foxborough, MA

2016 ISPE Boston Product Show

Come visit VTI at the 25th Anniversary ISPE Boston Area Chapter Product Show (Booth no. 87) at the Gillette Stadium in Foxborough, MA on October 5, 2016 Share List

San Diego, CA

2016 IVT Validation Week

Come see VTI at the IVT 22nd ANNUAL VALIDATION WEEK from October 18- 20th, 2016 at the Coronado Island Marriott in San Diego, CA. Share List

View all news ›

Latest News


New Presentation: SESSION 10: Setting Acceptance Criteria for Cleaning Validation

David Vincent, CEO of VTI recently presented at the 6th annual EU Validation Week in Amsterdam, Netherlands on March 17-19, 2015.  The presentation will provide the process of establishing the acceptance criteria to meet today’s regulatory environment. Additional information was provided by Dawn Tavalsky, on how to develop a three stage approach in setting acceptance criteria for cleaning process, including […]


New Article: Risk Management Analysis Techniques For Validation Programs

In recent years, the subject of quality risk management has become a major focus of the Food and Drug Administration (FDA). On April 9-11 2002, the FDA held a public meeting in Washington, D.C. The purpose of the meeting was for the public to comment on the following three FDA concept papers:  Premarketing Risk Assessment, […]